Free Trial

DiaMedica Therapeutics (DMAC) Insider Trading & Ownership

DiaMedica Therapeutics logo
$4.01 +0.38 (+10.47%)
Closing price 04:00 PM Eastern
Extended Trading
$4.02 +0.01 (+0.25%)
As of 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DiaMedica Therapeutics (NASDAQ:DMAC) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
7.30%
Number Of
Insiders Buying
(Last 3 Years)
5
Amount Of
Insider Buying
(Last 3 Years)
$9.38M
Number Of
Insiders Selling
(Last 3 Years)
0
Get DMAC Insider Trade Alerts

Want to know when executives and insiders are buying or selling DiaMedica Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

DMAC Insider Buying and Selling by Quarter

DiaMedica Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/28/2024Koch Thomas VonMajor ShareholderBuy1,200,000$2.50$3,000,000.00  
6/23/2023David J WambekeInsiderBuy38,364$3.91$150,003.24  
6/23/2023Dietrich John PaulsCEOBuy12,787$3.91$49,997.17  
6/23/2023Koch Thomas VonMajor ShareholderBuy1,470,588$3.40$4,999,999.20  
6/23/2023Randall Michael GiuffreDirectorBuy65,000$3.91$254,150.00  
6/23/2023Scott KellenCFOBuy10,000$3.91$39,100.00  
4/10/2023David J WambekeInsiderBuy468,750$1.60$750,000.00  
12/8/2022Randall Michael GiuffreDirectorBuy20,000$1.40$28,000.00  
12/6/2022Randall Michael GiuffreDirectorBuy2,300$1.35$3,105.00  
12/1/2022Randall Michael GiuffreDirectorBuy46,133$1.20$55,359.60  
11/29/2022Randall Michael GiuffreDirectorBuy18,125$1.19$21,568.75  
11/16/2022Dietrich John PaulsCEOBuy20,000$1.21$24,200.00  
(Data available from 1/1/2013 forward)

DMAC Insider Trading Activity - Frequently Asked Questions

The list of insiders at DiaMedica Therapeutics includes David J Wambeke, Dietrich John Pauls, Koch Thomas Von, Randall Michael Giuffre, and Scott Kellen. Learn more on insiders at DMAC.

7.30% of DiaMedica Therapeutics stock is owned by insiders. Learn more on DMAC's insider holdings.

The following insider purchased DMAC shares in the last 24 months: Koch Thomas Von ($3,000,000.00).

Insiders have purchased a total of 1,200,000 DMAC shares in the last 24 months for a total of $3,000,000.00 bought.

DiaMedica Therapeutics Key Executives

  • Mr. Dietrich John Pauls MBAMr. Dietrich John Pauls MBA (Age 53)
    President, CEO & Director
    Compensation: $818.61k
  • Mr. Scott Kellen CPA (Age 59)
    CFO & Corporate Secretary
    Compensation: $485.43k
  • Dr. Kirsten L. Gruis M.D. (Age 51)
    M.S., Independent Consultant
    Compensation: $449.29k
  • Dr. Ambarish Shah Ph.D.
    Chief Technology Officer
  • Mr. Dominic R. Cundari (Age 73)
    Chief Commercial Officer
  • Mr. David J. Wambeke (Age 40)
    Chief Business Officer
  • Dr. Lorianne K. Masuoka M.D. (Age 63)
    Chief Medical Officer


This page (NASDAQ:DMAC) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners